Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Daratumumab Quadruplet Supported Transplant-Ineligible MM
In the treatment of patients with newly diagnosed multiple myeloma (MM) who are not eligible for stem cell transplant or are transplant-deferred, adding subcutaneous daratumumab to bortezomib/lenalidomide/dexamethasone (D-VRd) significantly improves minimal residual disease (MRD) outcomes among patients, the first results…
English